About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Letter to the Editor
JoAnn Stubbings, BSPharm, MHCA
But in Some Instances, the Industry Is Pushing Back
The Food and Drug Administration, concerned about the quality of the generic drugs that represent 84 percent of U.S. prescriptions, is looking more closely at foreign manufacturing plants and weighing other changes in the generic approval process.
Health care professionals’ use of mobile devices is transforming clinical practice. Numerous medical software applications can now help with tasks ranging from information and time management to clinical decision-making at the point of care.
C. Lee Ventola, MS
Biomarkers and Combination Therapies May Lead to Disease-Modifying Treatments, Experts Say
Developing a disease-modifying treatment for Alzheimer’s disease has stymied researchers. A collaborative re-examination of premises that guided disappointing earlier trials is under way, with talk of new targets and combination therapies.
Attendees at the American Academy of Dermatology meeting found heightened interest in psoriasis treatments. The American College of Cardiology meeting included sessions on heparin versus bivalirudin and a controversy over renal denervation.
Your Actions Speak Louder Than Words When It Comes To Patient Safety
Matthew Grissinger, RPh, FASCP
The Impacts on Pharmacy Workload and Prescription Drug Abuse Are at Issue
FDA approvals, drug indications, and updates
Droxidopa (Northera) for neurogenic orthostatic hypotension, elosulfase alfa (Vimizim)for Morquio A syndrome, and sodium hyaluronate in phosphate-buffered saline (Monovisc) to address knee osteoarthritis
Marvin M. Goldenberg, PhD, RPh, MS
Agnes Cha, PharmD, AAHIVP, BCACP; and Aliaksandr Budovich, PharmD